Navigation Links
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
Date:11/2/2013

the CT and TT IL28B genotypes led to a reduced likelihood of achieving viral cure. In addition, more than half the patients in the study (20/36) have pre-existing HCV mutations. These include the Q80K variant in 12 of these patients, all of which had virologic responses to the faldaprevir-based triple direct-acting antiviral (DAA) regimen. Also in this trial, 19% of patients are African American.

"These results add to the growing body of data for HCV regimens containing our investigational compound, faldaprevir," said Peter Piliero, M.D., vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We are looking forward to the final results of this trial, as well as our other studies evaluating all-oral regimens, as researchers strive to make an interferon-free future a reality for a broad range of HCV patients."

This study contains three arms:

  • The first arm enrolled 12 patients and is evaluating faldaprevir 120mg once-daily (QD), PPI-668 200mg once-daily (QD) and deleobuvir 600mg twice-daily (BID) with ribavirin
  • The second arm enrolled 12 patients and is evaluating faldaprevir 120mg QD, PPI-668 200mg QD and deleobuvir 400mg BID with ribavirin
  • The third arm enrolled 12 patients and is evaluating faldaprevir 120mg QD, PPI-668 200mg QD and deleobuvir 600mg BID without ribavirin

All patients in the study have received at least 4 weeks of treatment and 97% (35/36) achieved LLOQ. To date, one patient who had pre-existing NS5A and NS5B mutations failed treatment. This patient had a partial response to treatment but developed viral breakthrough and was discontinued.

To date, there has been one treatment discontinuation due to adverse events. The patient self-discontinued at week 9 on treatment due to gastrointestinal side effects. This patient had undetectable levels of HCV RNA by day 10 of trea
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... /CNW/ - Protecting the health and safety of Canadians is our ... appropriate powers and tools at its disposal to help ensure that ... To that end, Health Canada ... Canada of all drug products from three ... , Apotex Pharmachem India Pvt Ltd , Apotex ...
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... market for molecular imaging informatics solutions including nuclear ... fusion and comparison. The study assesses the size ... between 2010 and 2013, and projects future growth ... well as the dynamics taking place in the ...
Breaking Medicine Technology:Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3
(Date:9/30/2014)... potential for doctors to measure damaging "brain tsunamis" ... moved a step closer to reality, thanks to ... Neuroscience Institute. , The research team, led by ... department of neurosurgery at the UC College of ... spread through an injured brain like tsunami wavescan ...
(Date:9/30/2014)... Sleep apnea is a potential health risk for millions of ... behind the disorder: a "fat" tongue. "This is the ... the tongue of obese patients with obstructive sleep apnea," study ... at the University of Pennsylvania Medical Center, said in a ... findings Oct. 1. Sleep apnea is a common disorder ...
(Date:9/30/2014)... Autism is no stranger to the children of ... is access to clinical services, including reliable diagnosis and ... example, validated for use in Swahili, a major language ... researchers at Brown University and the University of Georgia ... implemented at two sites in the country and found ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... Dynamic health trends, changing consumer ... the Bread Production industry over the past five ... their consumption of a variety of industry goods ... the market for white loaf bread and other ... introducing more nutritious products to attract health-conscious consumers, ...
Breaking Medicine News(10 mins):Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... Lung Association Urges Senate to Quickly Pass this ... Charles D. Connor, American Lung Association President and ... overwhelmingly voted in favor with a strong bipartisan ... to pass the Family Smoking Prevention and Tobacco ...
... Mo., April 2 Argus Health Systems, Inc., a ... an award from the Flaspohler Research Group as the ... Interest" in the 2008 PBM Survey of MCOs ... by survey participants based on specific attributes, including not ...
... always see what is in front of us? According to ... The City College of New York (CCNY), the answer is "no." ... by Professor Ro and colleagues from the University of Illinois demonstrates ... a trough. , "We may have our eyes open, but we ...
... attention about clinical productivity and adoption of Health IT ... www.usercentric.com ) - a user research firm based in ... healthcare industry called Usability Diagnostics ... targeted for these service offerings are: Electronic Health Records ...
... PHILADELPHIA, April 2, 2009 -- More than 6,000 ... allied health professionals will meet in Philadelphia for ... the American College of Physicians (ACP), April 23 ... Convention Center. , ACP is the largest specialty ...
... ALTO, Calif., April 2 Varian Medical Systems (NYSE: ... anniversary and a decade of growth and innovation in ... and security and inspection. , , Varian ... 2, 1999 following the division of Varian Associates, a ...
Cached Medicine News:Health News:U.S. House of Representatives Again Votes with a Strong Bipartisan Majority in Favor of Granting the U.S. FDA Regulatory Control Over Tobacco Products 2Health News:Argus Honored by Flaspohler Research Group as Highest-Rated PBM for 'No Conflicts of Interest' 2Health News:Neuroscientists demonstrate link between brainwave acticity and visual perception 2Health News:User Centric Offers New Service, Usability Diagnostics, to Measure HIT Usability 2Health News:User Centric Offers New Service, Usability Diagnostics, to Measure HIT Usability 3Health News:From the ethics of Dr. Frankenstein to preventing cardiovascular disease 2Health News:From the ethics of Dr. Frankenstein to preventing cardiovascular disease 3Health News:From the ethics of Dr. Frankenstein to preventing cardiovascular disease 4Health News:From the ethics of Dr. Frankenstein to preventing cardiovascular disease 5Health News:Varian Medical Systems to Celebrate Tenth Anniversary and Decade of Growth 2Health News:Varian Medical Systems to Celebrate Tenth Anniversary and Decade of Growth 3
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
The Horizontal-Vertical (H/V) lumbar valve system is the only differential pressure valve for lumbo-peritoneal shunting, which addresses orthostatic overdrainage....
10 overall length 4.5 from bend 250 mm. 90...
Wilson pituitary forcep, flattened tip, 3 mm bite, 145 mm effective....
Medicine Products: